The cannabinoid story is hardly new to biopharma. The first cannabinoid therapeutics were approved roughly two decades ago, but only four drugs targeting the brain's cannabinoid receptors have made it to market, targeting narrow indications associated with cancer, neuropathic pain, chemotherapy-induced nausea and vomiting (CINV) or cachexia.

PARIS – For those with access to the necessary drugs, HIV infection is now controllable in a way that seemed unthinkable not that long ago.